Felix Prehn, the founder of Goat Academy, is known for finding unique investment opportunities. One stock that stands out in 2025 is Stoke Therapeutics (ticker: STOK). This company is in the biotechnology field, which means it uses science to create new medicines that help people with rare diseases.
What Does Stoke Therapeutics Do?
Stoke Therapeutics focuses on rare diseases caused by problems in genes. Genes are like instructions in our bodies. If a gene is broken or missing, it can cause serious health issues. Stoke creates special drugs to help fix these problems. They use something called RNA medicines. RNA is a messenger in our cells that helps build proteins, which are the building blocks of our bodies. Stoke’s drugs change the RNA messages to help the body make more of what it needs, especially for the brain and eyes.
Main Focus: Dravet Syndrome
The main disease Stoke is working on is Dravet syndrome. This is a rare and severe type of epilepsy that causes seizures in babies. It is hard to treat, but Stoke’s drug has shown in tests that it can reduce seizures by about half in some children. The drug is now in the final stage of testing, with results expected in late 2027.
Other Projects
Stoke is also working on treatments for other rare conditions. These include Syngap1, a brain disorder that causes learning problems and seizures, Rett syndrome, which affects brain development in girls, and optic atrophy, an eye problem that can lead to vision loss.
Partnerships and Growth
Stoke works with larger companies like Acadia Pharmaceuticals and Biogen. These partnerships help share costs and bring in more expertise, making it easier and faster to develop new treatments.
Why Investors Are Interested
Many Wall Street analysts rate Stoke Therapeutics as a strong buy. Some have set a target price of$28, while the stock is currently trading around$13. This means there could be a big chance for growth if the company’s drugs are approved and successful.
Risks to Consider
Investing in biotechnology stocks can be risky. If the company’s drugs do not pass final tests, the stock price could fall quickly. It is important for investors to have a plan, use stop-loss orders (which are automatic sell orders to limit losses), and manage their risk carefully.
Conclusion
Stoke Therapeutics is a promising penny stock under$12, with a focus on rare diseases and strong partnerships. However, like all investments, it comes with risks. Learning how to research and manage stocks is key to long-term success.
For more about Felix Prehn and his approach to investing, visit the Felix Prehn Goat Academy page.